Moderate to severe dyspareunia.
Inactive steroid that is converted into active androgens and/or estrogens. Exact mechanism in treatment of vulvar and vaginal atrophy in menopausal women not fully established.
Reduced severity of dyspareunia.
Metabolism and Excretion: Metabolized via dehydrogenase, reductase, and aromatase to estradiol and testosterone.
TIME/ACTION PROFILE (improvement in dyspareunia severity)
- Undiagnosed abnormal genital bleeding;
- Current or history of breast cancer;
- OB: Lactation: Pedi: Only indicated in postmenopausal women
Use Cautiously in:
Adverse Reactions/Side Effects
GU: vaginal discharge
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Vag (Adults) Insert one vaginal insert at bedtime.
Vaginal insert: 6.5 mg
- Assess for pain during intercourse periodically during therapy.
- Deficient knowledge, related to medication regimen (Patient/Family/Teaching)
- Vag Insert vaginal insert at bedtime using applicator provided. Vaginal inserts can be stored at room temperature or refrigerated.
- Explain purpose of prasterone to patient. Instruct patient to read Instructions for Use before inserting prasterone.
- Inform patient that vaginal discharge and abnormal PAP smear findings may occur with prasterone.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications during therapy.
Decreased pain during intercourse.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Complete Product Information.